WallStreetZenWallStreetZen

NASDAQ: BCLI
Brainstorm Cell Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

BCLI earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$17.2M
Current Profit Margin
0%

BCLI Return on Equity

Current Company
N/A
Current Industry
-63.5%
Current Market
188%

Be the first to know when BCLI announces earnings.

BCLI Return on Assets

Current Company
-292.5%
Current Industry
2.9%
BCLI is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

BCLI Return on Capital Employed

Current Company
466.17%
Current Industry
19.5%
BCLI has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BCLI vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
BCLI$0.00-$16.48M-$17.19MN/AN/A
OKYO$0.00-$13.18M-$13.27MN/AN/A
XLO$0.00-$74.50M-$76.40MN/AN/A
FBIO$84.51M-$36.73M-$68.67M+25.75%N/A
ICU$0.00-$25.15M-$26.23MN/AN/A
View Top Biotech Stocks

BCLI earnings dates

Next earnings date
May 13, 2024

Brainstorm Cell Therapeutics Earnings & Revenue FAQ

What were BCLI's earnings last quarter?

On Invalid Date, Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 2023 earnings per share (EPS) of -$0.11, up 15.38% year over year. Total Brainstorm Cell Therapeutics earnings for the quarter were -$5.58 million. In the same quarter last year, Brainstorm Cell Therapeutics's earnings per share (EPS) was -$0.13.

If you're new to stock investing, here's how to buy Brainstorm Cell Therapeutics stock.

What was BCLI's earnings growth in the past year?

As of Q2 2024, Brainstorm Cell Therapeutics's earnings has grown year over year. Brainstorm Cell Therapeutics's earnings in the past year totalled -$17.19 million.

What is BCLI's earnings date?

Brainstorm Cell Therapeutics's earnings date is Invalid Date. Add BCLI to your watchlist to be reminded of BCLI's next earnings announcement.

What was BCLI's revenue last quarter?

On Invalid Date, Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Brainstorm Cell Therapeutics's revenue was $0.00.

What was BCLI's revenue growth in the past year?

As of Q2 2024, Brainstorm Cell Therapeutics's revenue has grown null year over year. Brainstorm Cell Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.